author-photo

Ai Li

Amgen

27

Papers

2599

Citations

Citation Trend

Filter By

Papers (22) Sort By

Journal Conference Others

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (323)
Phase 2, multicenter, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for resectable stage IIIB/C and IVM1a melanoma (MEL).

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (12)
Abstract B13: A phase 2, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs. surgery for resectable stage IIIB-IVM1a melanoma

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (35)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1344)
3330 Clinical benefits associated with durable response (DR) in patients (pts) with unresected stage IIIB/C/IV melanoma treated with talimogene laherparepvec (T-VEC) or GM-CSF in the randomized phase 3 OPTiM trial (NCT00769704)

2015 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.

2015 The Breast
Show All
- Source
- Cite
- Save
Citations (36)
1129TiPA PHASE 1B/2, MULTICENTER, OPEN LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF TALIMOGENE LAHERPAREPVEC (T-VEC) AND IPILIMUMAB (IPI) VERSUS IPI ALONE IN PREVIOUSLY UNTREATED, UNRESECTED, STAGE IIIB, IIIC, AND IV MELANOMA

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (4)
1102PRESULTS OF THE EXTENSION TRIAL OF OPTIM, A MULTICENTER, RANDOMIZED PHASE 3 TRIAL OF TALIMOGENE LAHERPAREPVEC (T-VEC) VS GM-CSF FOR UNRESECTED STAGE IIIB-IV MELANOMA

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial

2014 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)